newdrugapprovals.org
FDA approves first treatment Dupixent (Dupilumab) for chronic rhinosinusitis with nasal polyps
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolo…